HIV infection in the brain has been a proverbial black box for scientists since the development of antiretroviral therapy in the 1990s. "With the antiretroviral therapy, infected cells can go into a latent stage. Prior to this study, scientists could only study brain infection at autopsy. The new model allows scientists to backtrack, seeing the progression and development of HIV infection in the brain. Antiretroviral drugs, the therapy of choice for HIV, cannot enter the brain so easily," said Roda.
Team tests best delivery mode for potential HIV vaccine: Optimized immunizations reliably elicit protective antibodies in preclinical study, marking an important milestone on the way to an effective H
"That caused significant concern that the immunogen wouldn't consistently trigger an effective immune response in all individuals in a human clinical trial." Neutralizing antibodies are a key component of an effective immune response. This group of laboratories in collaboration with Darrell J. Irvine, Ph.D., professor at MIT, and Rogier W. Sanders, Ph.D., professor at the University of Amsterdam, provided the cutting-edge immunogens tested in the study. Non-human primates, and especially rhesus macaques, are considered the most appropriate pre-clinical model for HIV vaccine studies, because their immune system most closely resembles that of humans. Their latest study, published in the current issue of Immunity, demonstrates that optimizing the mode and timing of vaccine delivery is crucial to inducing a protective immune response in a preclinical model.collected by :Lucy William
To follow all the new news about
No comments:
Post a Comment